Longbow takes stake in tissue regen firm
This article was originally published in Clinica
Executive Summary
UK tissue regeneration products developer BioCeramic Therapeutics (BCT) today announced it has closed a £1.2m financing round, which was led by new investor Longbow Capital. The latter invested £400,000, with Imperial Innovations contributing £300,000 and other existing shareholders making up the remainder of the funds. The new capital will be used by London-based BCT to prepare for the commercialisation of its first products, which include bone graft substitutes, in 2010. The financing follows the election of Dr Stephan Rietiker to the post of chairman (www.clinica.co.uk, October 19 2009).